Literature DB >> 21716207

Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels.

A Rivkina1, G Vitols, M Murovska, S Lejniece.   

Abstract

UNLABELLED: Serum thymidine kinase (TK), zeta-associated protein of 70 kDa (ZAP-70) and CD38 levels have been shown to be correlated with survival in chronic lymphocytic leukaemia (CLL). AIM: To investigate the possible correlations between TK, ZAP-70 and CD38 levels as prognostic markers in new diagnosed Rai stages of CLL patients.
METHODS: 120 CLL patients were enrolled. ELISA was used to measure serum TK level, flow cytomerty - to determine ZAP-70 and CD38 expression applying ZAP-70 Kit and monoclonal antibody to CD38, respectively.
RESULTS: Significantly higher levels of TK were found in the high progression group of CLL patients that corresponded to stage II (Rai classification). An elevated level of TK, CD38 and ZAP-70 together was also found in the II stage. The coefficient of correlation between CD38 and ZAP-70 is reliable (p < 0.001). There is also a correlation between the level of TK and the disease stage (p < 0.05). Other parameters do not show this correlation.
CONCLUSION: The determination of TK, ZAP-70 and CD38 together allows patients susceptible to a possible stage of the disease, to be identified. Estimation of the factors at an early stage of the disease may allow an earlier commencement of treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21716207

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  2 in total

1.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

2.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.